Advertisement

Breast Cancer Research and Treatment

, Volume 43, Issue 2, pp 183–190 | Cite as

Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications

  • Lucia Del Mastro
  • Marco Venturini
  • Mario Roberto Sertoli
  • Riccardo Rosso
Article

Abstract

Background: The role of amenorrhea induced by chemotherapyin premenopausal women with early breast cancer isvery controversial. Analyses by various authors of theeffect of drug-induced amenorrhea (DIA) on treatment outcomehave yielded conflicting results. In order to gaininsight into the role of DIA, we reviewedall published data addressing the issue of DIAas a prognostic factor. Methods: Computerised and manualsearches were conducted of relevant studies published from1966 to 1995. Results: Thirteen studies involving 3929patients were selected. In two papers, the prognosticrole of DIA was analysed in three andtwo different groups of patients, respectively. Overall, 16groups of patients were evaluated. With 12 groups,a higher disease free survival was observed inpatients developing DIA compared to those who didnot. This difference was statistically significant in eightgroups. Data on overall survival, reported in onlyfive studies, indicated that it was always improvedin patients who became amenorrheic. Conclusions: Available dataon the role of DIA support its importanceas a favorable prognostic factor for early breastcancer patients. However, due to the possible biasesof this type of evaluation, this result shouldbe interpreted with caution.

amenorrhea breast neoplasms drug therapy prognosis review 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fisher B, Carbone P, Economu SG, Frelick R, Glass A, Lerner H, Redmond C, Zelen M, Band P, Katrych DL, Wolmark N, Fisher ER: L-phenylalaline mustard (L-PAM) in the management of primary breast cancer: a report of early findings. N Engl J Med 292: 117–122, 1975Google Scholar
  2. 2.
    Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405–410, 1976Google Scholar
  3. 3.
    Goldhirsch A, Wood WC, Senn HJ, Glick JH, Gelber RD: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87: 1441–1445, 1995Google Scholar
  4. 4.
    Bonadonna G, Valagussa P: Treating early breast cancer. Lancet 339: 675, 1992Google Scholar
  5. 5.
    Del Mastro L, Costantini M, Bianco AR: Adjuvant chemotherapy in breast cancer. N Engl J Med 333: 596, 1995Google Scholar
  6. 6.
    Collichio F, Pandya K: Amenorrhea following chemotherapy for breast cancer: effect on disease-free survival. Oncology 8: 45–52, 1994Google Scholar
  7. 7.
    Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339: 1–15;71–85, 1992Google Scholar
  8. 8.
    Editorial: Adjuvant systemic therapy for early breast cancer. Lancet 339: 27, 1992Google Scholar
  9. 9.
    Editorial: Ovarian ablation in early breast cancer: phoenix arisen? Lancet 339: 95–96, 1992Google Scholar
  10. 10.
    Goldhirsch A, Gelber RD, Castiglione M: The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. Ann Oncol 1: 183–188, 1990Google Scholar
  11. 11.
    Rubens RD, Knight RK, Fentiman IS, Howell A, Crowther D, George WD, Hayward JL, Bulbrook RD, Chaudary M, Bush H, Sellwood RA, Howat JMT: Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet 1: 839–843, 1983Google Scholar
  12. 12.
    Brincker H, Rose C, Rank F, Mouridsen HT, Jacobsen A, Dombernowsky P, Panduro J, Andersen KW: Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol 5: 1771–1778, 1987Google Scholar
  13. 13.
    Brincker H, Mouridsen HT, Andersen KW, Rose C, Dombernowsky P: Castration induced by cytotoxic chemotherapy. J Clin Oncol 7: 679–680, 1989Google Scholar
  14. 14.
    Ludwig Breast Cancer Study Group: A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three lymph nodes. Cancer Res 45: 4454–4459, 1985Google Scholar
  15. 15.
    Beex LVAM, Mackenzie MA, Raemaekers JMM, Smals AGH, Benraad ThJ, Kloppenborg PWC: Adjuvant chemotherapy in premenopausal patients with primary breast cancer; relation to drug-induced amenorrhoea, age and the progesterone receptor status of the tumour. Eur J Cancer Clin Oncol 24: 719–721, 1988Google Scholar
  16. 16.
    The International Breast Cancer Study Group: Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients. Ann Oncol 1: 30–35, 1990Google Scholar
  17. 17.
    Richards MA, O'Reilly SM, Howell A, George WD, Fentiman IS, Chaudary MA, Crowther D, Rubens RD: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial. J Clin Oncol 8: 2032–2039, 1990Google Scholar
  18. 18.
    Tormey DC, Gray R, Gilchrist K, Grage T, Carbone PP, Wolter J, Woll JE, Cummings GJ: Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus Tamoxifen compared with CMF for premenopausal breast cancer patients. Cancer 65: 200–206, 1990Google Scholar
  19. 19.
    Bianco AR, Del Mastro L, Gallo C, Perrone F, Matano E, Pagliarulo C, De Placido S: Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer 63: 799–803, 1991Google Scholar
  20. 20.
    Tormey DC, Gray R, Abeloff MD, Roseman DL, Gilchrist KW, Barylak EJ, Stott P, Falkson G: Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 110: 1848–1856, 1992Google Scholar
  21. 21.
    Campora E, Pronzato P, Amoroso D, Bertelli G, Venturini M, Baldini E, Brunetti I, Sertoli MR, Conte PF, Rosso R: Prognostic factors in node positive primary breast cancer patients treated with adjuvant CMF. Anticancer Res 12: 1555–1558, 1992Google Scholar
  22. 22.
    Reyno LM, Levine MN, Skingley P, Arnold A, Zahra HA: Chemotherapy induced amenorrhoea in a randomised trial of adjuvant chemotherapy duration in breast cancer. Eur J Cancer 29A: 21–23, 1993Google Scholar
  23. 23.
    Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C: Adjuvant cyclophosphamide, methotrexate and fluorouracil in node positive breast cancer. The results of 20 years of follow-up. N Engl J Med 332: 901–906, 1995Google Scholar
  24. 24.
    Rose DP, Davis TE: Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet i: 1174–1176, 1977Google Scholar
  25. 25.
    Cobleigh MA, Bines J, Lincoln ST, Wolter JM: Amenorrhea following adjuvant chemotherapy for breast cancer. [Abstract.] Proc Am Soc Clin Oncol 13: 63, 1994Google Scholar
  26. 26.
    Mehta RR, Beattie CW, Das Gupta TK: Endocrine profile in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 20: 125–132, 1991Google Scholar
  27. 27.
    Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1: 710–719, 1983Google Scholar
  28. 28.
    Mantel N, Byar DP: Evaluation of response-time data involving transient states: an illustration using heart transplant data. J Am Stat Assoc 69: 81–86, 1974Google Scholar
  29. 29.
    Cox DR: Regression models and life-tables. J R Stat Soc (B) 34: 187–220, 1972Google Scholar
  30. 30.
    Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 2: 104–107, 1896Google Scholar
  31. 31.
    Kaufmann M, Jonat W, Kleeberg U, Eiermann W, Janicke F, Hilfrich J, Kreienberg R, Albrecht M, Weitzel HK, Schmid H, Strunz P, Schachner-Wunschmann E, Bastert G, Maass H: Goserelin, a depot gonadotropin-releasing hormone agonist in the treatment of pre-menopausal patients with metastatic breast cancer. J Clin Oncol 7: 1113–1119, 1989Google Scholar
  32. 32.
    Dnistrian AM, Schwartz MK, Fracchia AA, Kaufman RJ, Hakes TB, Currie VE: Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients. Cancer 51: 803–807, 1983Google Scholar
  33. 33.
    Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. JAMA 273: 542–547, 1995Google Scholar
  34. 34.
    Fisher B, Costantino J, Wickerham L, Redmond C, Wolmark N, Margolese R, Bowman D, Dimitrov N, Robidoux A, Glass A: Adjuvant therapy for node-negative breast cancer: an update of NSABP findings. [Abstract.] Proc Am Soc Clin Oncol 12: 69, 1993Google Scholar
  35. 35.
    Sertoli MR, Bruzzi P, Pronzato P, Queirolo P, Del Mastro L, Venturini M, Vigani A, Bertelli G, Campora E, Boccardo F, Monzeglio C, Paganini E, Pastorino G, Canavese G, Catturich A, Cafiero F, Vecchio C, Miccoli P, Rubagotti A, Rosso R: Randomized cooperative study of perioperative chemotherapy in breast cancer. J Clin Oncol 13: 2712–2721, 1995Google Scholar
  36. 36.
    De La Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, Durand JC, Pouillart P, Magdelenat H, Fourquet A: Age as prognostic factor in premenopausal breast carcinoma. Lancet 341: 1039–1043, 1993Google Scholar
  37. 37.
    Rivkin SE, Green S, O'Sullivan J, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Osborne CK: Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node positive, and estrogen receptor-positive breast cancer patients. A Southwest Oncology Group Study. J Clin Oncol 14: 46–51, 1996Google Scholar
  38. 38.
    Al-Azzawi F, Hart DM, Lindsay R: Long term effect of oestrogen replacement therapy on bone mass as measured by dual photon absoptiometry. Br Med J 294: 1261–1262, 1987Google Scholar
  39. 39.
    Witteman JCM, Grobbee DE, Kok FJ, Hofman A, Valkenburg HA: Increased risk of atherosclerosis in women after the menopause. Br Med J 298: 642–644, 1989Google Scholar
  40. 40.
    Palmer JR, Rosenberg L, Shapiro S: Reproductive factors and risk of myocardial infarction. Am J Epidemiol 136: 408–416, 1992Google Scholar
  41. 41.
    Vingerling JR, Dielemans I, Witteman JCM, Hofman A, Grobbee DE, Jong PTVM: Macular degeneration and early menopause: a case-control study. Br Med J 310: 1570–1571, 1995Google Scholar
  42. 42.
    Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14: 1718–1729, 1996Google Scholar
  43. 43.
    World Health Organization: Technical Report Series 670: Research on the menopause. Geneva, Switzerland, WHO, 1991Google Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Lucia Del Mastro
    • 1
  • Marco Venturini
    • 1
  • Mario Roberto Sertoli
    • 1
  • Riccardo Rosso
    • 1
  1. 1.Oncologia medica 1Istituto Nazionale per la Ricerca sul CancroGenovaItaly

Personalised recommendations